Alvotech
AVT16
ulcerative colitis, Crohn’s disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on AVT16 for ulcerative colitis, Crohn’s disease is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“If approved, AVT16 would add to the range of biosimilar options available to patients and healthcare providers in the United States.”